Bi-parametric Screening MRI for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Cynthia Knauer, Lake Success, NY
Prostate Cancer+3 More
Bi-parametric MRI - DiagnosticTest
Eligibility
18 - 65
Male
What conditions do you have?
Select

Study Summary

To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols.

Eligible Conditions

  • Prostate Cancer
  • Magnetic Resonance Imaging (MRI)
  • Population at Risk

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 5 years

3 months
Proportion of suspicious lesions on MRI in men with PSA less than 2.5 ng/ml
Prostate cancer detection rate using 3T bpMRI in patients with high risk and suspicious lesions on bpMRI
To assess prostate cancer detection rate using 3T bpMRI in patients with high risk and suspicious lesions on bpMRI
5 years
Association of whether findings on bpMRI and serum PSA (i.e. PSA density) are associated with future diagnosis of prostate cancer.
To correlate bpMRI findings with future changes in PSA
To determine whether findings on bpMRI and serum PSA (i.e. PSA density) are associated with future diagnosis of prostate cancer.

Trial Safety

Trial Design

1 Treatment Group

Bi-parametric Screening MRI
1 of 1
Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: Bi-parametric Screening MRI · No Placebo Group · N/A

Bi-parametric Screening MRI
DiagnosticTest
Experimental Group · 1 Intervention: Bi-parametric MRI · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years
Closest Location: Cynthia Knauer · Lake Success, NY
N/AFirst Recorded Clinical Trial
1 TrialsResearching Prostate Cancer
0 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · Male Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References